Kewalramani Reshma sold 11,866 shares of VERTEX PHARMACEUTICALS INC MA at $531.53 for −$6.31M on Nov 6, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
CEO & President
CEO & President
Filed Nov 10, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$6,307,134.98Shares × reported price
Shares traded
11,866Common Stock
Price per share
$531.53Reported price. Read footnotes for ranges.
% of reported position traded
12.07%This security and ownership context
Holdings after
86,471Direct
Trade date
Nov 6, 2026Sell
Filed
Nov 10, 2026, 4:20 PM ET4-day reporting delay
Accession
0000875320-26-000293Code S · Transaction 397035
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 98,337 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

VRTX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
VRTX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 17, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −7.7%1w ago +2%1d ago −1%
Returns since7d30d90d180d1y

Footnotes in full

F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 8/5/2026.